Cardiovascular Safety of Inhaled Long-Acting Bronchodilators in Individuals With Chronic Obstructive Pulmonary Disease
about
Combined aclidinium bromide and long-acting beta 2 -agonist for COPDNew combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectivesLong acting β2-adrenocepter agonists are not associated with atrial arrhythmias after pulmonary resectionImpact of airflow limitation in chronic heart failure.Inhaled β-agonist does not modify sympathetic activity in patients with COPD.Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial.Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis.Phenotype of normal spirometry in an aging population.Risk of Stroke and Post-Stroke Adverse Events in Patients with Exacerbations of Chronic Obstructive Pulmonary DiseasePhenotype of Spirometric Impairment in an Aging PopulationRisk of cardiovascular events after initiation of long-acting bronchodilators in patients with chronic obstructive lung disease: A population-based study.β-Blockers and chronic obstructive pulmonary disease: inappropriate avoidance?Safety of tiotropium through the Handihaler: why did meta-analyses and database studies appear to give a false alarm?Year in review 2013: Chronic obstructive pulmonary disease, asthma and airway biology.Comorbidity of heart failure and chronic obstructive pulmonary disease: more than coincidence.Chronic obstructive pulmonary disease in heart failure: accurate diagnosis and treatment.Umeclidinium/vilanterol combination inhaler efficacy and potential impact on current chronic obstructive pulmonary disease management guidelines.Epidemiology of Chronic Obstructive Pulmonary Disease (COPD) in Aging Populations.Does Cardiovascular Comorbidity Influence the Prescribing of Bronchodilators in Chronic Obstructive Pulmonary Disease?An Official American Thoracic Society Workshop Report: Evaluation and Management of Asthma in the Elderly.Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care.Obstructive Ventilatory Disorder in Heart Failure-Caused by the Heart or the Lung?Safety of inhaled long-acting anti-muscarinic agents in COPD.Comparative Cardiovascular and Cerebrovascular Safety of Inhaled Long-Acting Bronchodilators in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.Heart failure, chronic obstructive pulmonary disease, and asthma: numbers, facts, and challengesImpact of long-acting bronchodilators and exposure to inhaled corticosteroids on mortality in COPD: a real-life retrospective cohort study.Authors' response to Walker et al.Inhaled bronchodilators and acute myocardial infarction: a nested case-control study.Factors associated with the incidence of serious adverse events in patients admitted with COPD acute exacerbation.Indacaterol for the treatment of chronic obstructive pulmonary disease.Concomitant pulmonologist and primary care for chronic obstructive pulmonary disease: a population study.Olodaterol + tiotropium bromide for the treatment of COPD.
P2860
Q24187613-60657DA7-2CC2-4E86-82EA-F992BE2736D7Q27024384-AFFBFE85-1B2E-4174-A40A-1A54B5AA6266Q30851904-F436C032-331D-484F-991F-8C02B0CA2A93Q33603101-4C9EF3BF-B5ED-4913-98CE-76DFC88E6A9FQ35618080-F590694C-15D5-4144-81BB-40C69C84AB6FQ35762406-6407A5EF-4BD5-4D29-958B-FB3F12279AEBQ35778149-5854A70D-3A5E-4DFE-94B7-A2CC9C0CECFCQ36185922-75EFD513-3D5B-4A31-9E08-8223EA90F1FFQ36242932-C7402BA4-EFA6-40EC-B240-47C78071E83BQ36778591-02EABDF1-D6FD-4BC3-AF2D-2042D8D55C0BQ37315758-9CFB0575-769C-4292-8BB0-E1E331A3F652Q38150473-A45F6015-4778-4803-BBFB-5A79F4F3CE48Q38189313-FD8E9F86-87AB-4563-954C-C8D5AB48A2BAQ38202680-25DB62E4-B714-4D7A-87B8-BE4C32EA894BQ38224810-3A19127C-96DB-4283-9E13-FDF7263B730CQ38262835-807CFB24-53A4-4A8D-B222-426F62EE0C1BQ38322792-5B4B794D-780C-473E-9E08-6B6F86BF9F9AQ38656722-DF7F5C36-93A2-448A-9FE7-E8BF65D75B54Q38749254-718C326B-1E7E-44B6-94F2-2FB15345426EQ38796735-93146AA9-D798-4425-A65B-D265268A36DFQ38944856-399CEF68-82B2-4090-A0D6-D49C3E7030D0Q39000103-642F230E-F84F-451D-9954-4EE5CD6AF891Q39232425-EBED283A-886C-4088-A7C9-89BA37BCD8C3Q40957631-3F1AB65C-3112-48DF-89C2-ED904A137784Q42389709-32839FC4-CFD6-4763-8551-7B999AD12248Q45952249-0B5B28FE-C557-4E79-8C1F-A22715507D48Q46038122-1C7EB277-48BF-4457-B508-3411D4270BF2Q47107761-C5E9DE73-6990-44F9-924B-217AF32CD8B5Q47825043-FCF66433-71C5-441E-B22A-27956E441CE2Q48059168-1255DA4B-AA18-41B6-BE88-06E110CF94FFQ49556548-C39D575E-0AA5-49F7-B5AC-626E54C90FC5Q51545895-9DF68BCA-35F1-4329-B0FA-167B31B8EBBA
P2860
Cardiovascular Safety of Inhaled Long-Acting Bronchodilators in Individuals With Chronic Obstructive Pulmonary Disease
description
scientific article published on 01 July 2013
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 2013
@uk
name
Cardiovascular Safety of Inhal ...... Obstructive Pulmonary Disease
@en
Cardiovascular Safety of Inhal ...... Obstructive Pulmonary Disease
@nl
type
label
Cardiovascular Safety of Inhal ...... Obstructive Pulmonary Disease
@en
Cardiovascular Safety of Inhal ...... Obstructive Pulmonary Disease
@nl
prefLabel
Cardiovascular Safety of Inhal ...... Obstructive Pulmonary Disease
@en
Cardiovascular Safety of Inhal ...... Obstructive Pulmonary Disease
@nl
P2093
P1476
Cardiovascular safety of inhal ...... obstructive pulmonary disease
@en
P2093
Andrea Gershon
Andrew Calzavara
Matthew B Stanbrook
Ruth Croxford
P304
P356
10.1001/JAMAINTERNMED.2013.1016
P577
2013-07-01T00:00:00Z